Dosimetric Characterization of an Abscopal Response in a Patient With Oligometastatic Melanoma Undergoing Concurrent Treatment With Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)

Abstract

Recently, preclinical and clinical evidence has shown that a synergy may exist between radiation and immune check-point therapies
such as pembrolizumab. Radiation has been shown to activate the immune system, and in combination with immunotherapy may
lead to systemic anti-tumor responses. However, the exact dose regimens needed to induce synergistic responses are unclear. Here,
we report a dosimetric characterization of a patient treated with stereotactic radiation in combination with immune check-point
therapy.